Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Conditions: Tuberculosis, Multidrug-Resistant; Tuberculosis; Tuberculosis, Pulmonary; Mycobacterium Infections; Bacterial Infections; Gram-Positive Bacterial Infections Interventions: Drug: Bedaquiline; Drug: Delamanid; Drug: Clofazimine; Drug: Linezolid; Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines Sponsors: Médecins Sans Frontières, France; Partners in Health; Harvard Medical School; Epicentre; Institute of Tropical Medicine, Belgium; Socios En Salud, Peru; Interactive Research and Development Not yet recru...
Source: ClinicalTrials.gov - April 1, 2019 Category: Research Source Type: clinical trials
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB
Condition: Tuberculosis, Multidrug-Resistant Interventions: Drug: Delamanid; Drug: Levofloxacin; Drug: Bedaquiline; Drug: Clofazimine; Drug: Linezolid; Combination Product: WHO approved MDR-TB treatment regimens Sponsors: Boston University; United States Department of Defense; Novartis Pharmaceuticals; Pfizer; Otsuka Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 4, 2019 Category: Research Source Type: clinical trials
